Metabolism of Lithium Gamma-Linolenate in Human Tumors
Author Information
Author(s): R de Antueno, M Elliot, G Ells, P Quiroga, K Jenkins, D Horrobin
Primary Institution: Scotia Research Institute
Hypothesis
Can lithium gamma-linolenate (LiGLA) be effectively metabolized by human carcinomas?
Conclusion
The study found that LiGLA is well tolerated and leads to increased levels of gamma-linolenic acid (GLA) and dihomo-gamma-linolenic acid (DGLA) in various tissues.
Supporting Evidence
- LiGLA was administered to mice and showed a maximum uptake of radioactivity in organs 30 minutes after infusion.
- GLA and DGLA levels remained higher in tumor tissues compared to liver and plasma for up to 96 hours.
- Different human carcinoma cell lines showed varying abilities to metabolize GLA and produce DGLA and AA.
Takeaway
This study looked at how a special fat called LiGLA is used by cancer cells, showing it can stay in tumors for a long time and might help in cancer treatment.
Methodology
The study involved in vivo experiments with nude mice and in vitro experiments with human carcinoma cell lines to assess the metabolism of LiGLA.
Limitations
The study was conducted in a mouse model, which may not fully replicate human responses.
Participant Demographics
Seven-week-old athymic CD1BR (nu/nu) mice were used in the study.
Want to read the original?
Access the complete publication on the publisher's website